Targeting pancreatic cancer immune evasion by inhibiting histone deacetylases
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting pancreatic cancer immune evasion by inhibiting histone deacetylases
Authors
Keywords
-
Journal
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 28, Issue 18, Pages 1934-1945
Publisher
Baishideng Publishing Group Inc.
Online
2022-05-06
DOI
10.3748/wjg.v28.i18.1934
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pancreatic Cancer with Mutation in BRCA1/2, MLH1, and APC Genes: Phenotype Correlation and Detection of a Novel Germline BRCA2 Mutation
- (2022) Maria Teresa Vietri et al. Genes
- Targeted Cancer Therapy Based on Acetylation and Deacetylation of Key Proteins Involved in Double-Strand Break Repair
- (2022) Xiwen Wang et al. Cancer Management and Research
- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- An overview of genetic mutations and epigenetic signatures in the course of pancreatic cancer progression
- (2021) Aamir Ali Khan et al. CANCER AND METASTASIS REVIEWS
- HDAC5 loss impairs RB repression of pro-oncogenic genes and confers CDK4/6 inhibitor resistance in cancer
- (2021) Yingke Zhou et al. CANCER RESEARCH
- Structural basis for the regulation of nucleosome recognition and HDAC activity by histone deacetylase assemblies
- (2021) Jung-Hoon Lee et al. Science Advances
- Research Progress of Pancreas-Related Microorganisms and Pancreatic Cancer
- (2021) Wenqing Zhang et al. Frontiers in Oncology
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Co-encapsulation of gemcitabine and tocotrienols in nanovesicles enhanced efficacy in pancreatic cancer
- (2021) Geetha Maniam et al. Nanomedicine
- Recent developments of HDAC inhibitors: Emerging indications and novel molecules
- (2021) Andrey D. Bondarev et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Novel Suberoylanilide Hydroxamic Acid Analogs Inhibit Angiogenesis and Induce Apoptosis in Breast Cancer Cells
- (2021) Gopikrishna Moku et al. Anti-Cancer Agents in Medicinal Chemistry
- Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes
- (2021) Fan Luo et al. Cancer Cell International
- Recent advances in nanomedicine-based delivery of histone deacetylase inhibitors for cancer therapy
- (2021) Dina A Hafez et al. Nanomedicine
- HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity
- (2021) Dimitris Karagiannis et al. Cancers
- HDAC2 facilitates pancreatic cancer metastasis
- (2021) Lukas Krauß et al. CANCER RESEARCH
- Medicinal chemistry updates of novel HDACs inhibitors (2020 to present)
- (2021) Xingrui He et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Anti-Proliferative, Anti-Angiogenic and Safety Profiles of Novel HDAC Inhibitors for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- (2021) Zohaib Rana et al. Pharmaceuticals
- Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
- (2020) Louis Buscail et al. Nature Reviews Gastroenterology & Hepatology
- Cancer vaccines: Targeting KRAS-driven cancers
- (2020) Ying Zhang et al. Expert Review of Vaccines
- Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified
- (2020) Sehui Kim et al. VIRCHOWS ARCHIV
- Treatment patterns and outcomes in pancreatic cancer: Retrospective claims analysis
- (2020) Yunes Doleh et al. Cancer Medicine
- Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability
- (2020) Giorgio Milazzo et al. Genes
- The Contribution of Epigenetics to Cancer Immunotherapy
- (2020) Lorea Villanueva et al. TRENDS IN IMMUNOLOGY
- Molecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion
- (2020) Li-Lian Gan et al. Cancers
- Histone acetyltransferase 1 is a succinyltransferase for histones and non‐histones and promotes tumorigenesis
- (2020) Guang Yang et al. EMBO REPORTS
- Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer
- (2020) Tyler R. McCaw et al. Cancer Medicine
- Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis
- (2019) Divya Thomas et al. Molecular Cancer
- HDAC3 modulates cancer immunity via increasing PD-L1 expression in pancreatic cancer
- (2019) Guofu Hu et al. PANCREATOLOGY
- Zinc-dependent deacetylase (HDAC) inhibitors with different ZBG groups
- (2019) Yan Li et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Traditional and Novel Mechanisms of Heat Shock Protein 90 (HSP90) Inhibition in Cancer Chemotherapy Including HSP90 Cleavage
- (2019) Sangkyu Park et al. Biomolecules & Therapeutics
- Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
- (2019) Debarati Banik et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment
- (2019) Chin-King Looi et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cells
- (2019) Hehe Li et al. Cell and Bioscience
- Human Pancreatic Carcinoma-Associated Fibroblasts Promote Expression of Co-inhibitory Markers on CD4+ and CD8+ T-Cells
- (2019) Laia Gorchs et al. Frontiers in Immunology
- Novel discoveries targeting gemcitabine‐based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination?
- (2019) Wenhao Luo et al. Cancer Medicine
- Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy
- (2019) Richard S. Laschanzky et al. Cancers
- Histone deacetylase inhibition promotes intratumoral CD8+ T-cell responses, sensitizing murine breast tumors to anti-PD1
- (2019) Tyler R. McCaw et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications
- (2019) Xiaomeng Liu et al. Molecular Cancer
- Clinicopathological features and prediction values of HDAC1, HDAC2, HDAC3, and HDAC11 in classical Hodgkin lymphoma
- (2018) Renhong Huang et al. ANTI-CANCER DRUGS
- The role of histone deacetylase 1 in distant metastasis of pancreatic ductal cancer
- (2018) Go Shinke et al. CANCER SCIENCE
- Targeting the tumour stroma to improve cancer therapy
- (2018) Kenneth C. Valkenburg et al. Nature Reviews Clinical Oncology
- Depletion of HDAC1, 7 and 8 by Histone Deacetylase Inhibition Confers Elimination of Pancreatic Cancer Stem Cells in Combination with Gemcitabine
- (2018) Mao-Hua Cai et al. Scientific Reports
- Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment
- (2018) Etienne D. Foucher et al. Frontiers in Immunology
- Entinostat in combination with nivolumab for patients with advanced cholangiocarcinoma and pancreatic adenocarcinoma.
- (2018) Marina Baretti et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined HDAC and BET Inhibition Enhances Melanoma Vaccine Immunogenicity and Efficacy
- (2018) Alexander Badamchi-Zadeh et al. JOURNAL OF IMMUNOLOGY
- CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review
- (2018) Bagher Farhood et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Optimizing the outcomes of pancreatic cancer surgery
- (2018) Oliver Strobel et al. Nature Reviews Clinical Oncology
- Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs
- (2018) Brian J. Christmas et al. Cancer Immunology Research
- Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
- (2017) Vinod P. Balachandran et al. NATURE
- Molecular Characteristics of Pancreatic Ductal Adenocarcinomas with High-Grade Pancreatic Intraepithelial Neoplasia (PanIN) Are Different from Those without High-Grade PanIN
- (2017) Tetsuyuki Miyazaki et al. PATHOBIOLOGY
- HDAC inhibitors enhance the immunotherapy response of melanoma cells
- (2017) Laurence Booth et al. Oncotarget
- JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer
- (2017) Chunwan Lu et al. OncoImmunology
- The TGF-β/Smad4 Signaling Pathway in Pancreatic Carcinogenesis and Its Clinical Significance
- (2017) Sunjida Ahmed et al. Journal of Clinical Medicine
- The histone deacetylase inhibitor valproic acid inhibits NKG2D expression in natural killer cells through suppression of STAT3 and HDAC3
- (2017) Lulu Ni et al. Scientific Reports
- A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance
- (2017) Hee Seung Lee et al. Scientific Reports
- HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma
- (2016) Hong Zheng et al. CLINICAL CANCER RESEARCH
- Combination of HDAC inhibitor TSA and silibinin induces cell cycle arrest and apoptosis by targeting survivin and cyclinB1/Cdk1 in pancreatic cancer cells
- (2015) Wan Feng et al. BIOMEDICINE & PHARMACOTHERAPY
- FDA Approves New Agent for Multiple Myeloma
- (2015) M. P. Fenichel JNCI-Journal of the National Cancer Institute
- Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial
- (2015) Lee M Krug et al. LANCET ONCOLOGY
- Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity
- (2015) K Cao et al. ONCOGENE
- FDA Approves New Agent for Multiple Myeloma
- (2015) M. P. Fenichel JNCI-Journal of the National Cancer Institute
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- The Anti-Tumor Effect of HDAC Inhibition in a Human Pancreas Cancer Model Is Significantly Improved by the Simultaneous Inhibition of Cyclooxygenase 2
- (2013) Olivier Peulen et al. PLoS One
- Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer
- (2012) Dmitriy I Dovzhanskiy et al. BMC CANCER
- Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma
- (2011) Karen M VanderMolen et al. JOURNAL OF ANTIBIOTICS
- Epigenetic Enhancement of Antigen Processing and Presentation Promotes Immune Recognition of Tumors
- (2008) A. F. Setiadi et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started